Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Fineline Cube Jan 20, 2026
Company Deals

Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders

Fineline Cube Nov 8, 2025

In a high‑profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO:...

Policy / Regulatory

NHSA Pilot AI Review Accelerates Full‑Process Medical Insurance Assessment in 7 Chinese Provinces

Fineline Cube Nov 8, 2025

The National Healthcare Security Administration (NHSA) has announced a three‑phase, AI‑powered review pilot covering Beijing,...

Policy / Regulatory

US FDA’s CNPV Fast‑Track Program Expands to 15 Drugs, Cutting Review Time to Months

Fineline Cube Nov 8, 2025

The Commissioner’s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two‑batch...

Company Deals

Sichuan Biokin Launches on HKEX, Raises HK$3.3 B in $389/Share Offering – A Milestone for China’s Biotech

Fineline Cube Nov 8, 2025

China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced its successful initial public offering (IPO)...

Medical Device

LifeTech Scientific Secures NMPA Approval for G‑Branch TAAA Stent‑Graft System

Fineline Cube Nov 8, 2025

LifeTech Scientific Corporation (HKG: 1302) announced that China’s National Medical Products Administration (NMPA) has granted...

Company

Viatris Posts Q3 2025 Revenue Dip, Highlights Emerging‑Market Branded Growth and Aculys Pharma Acquisition

Fineline Cube Nov 8, 2025

U.S.‑based Viatris Inc. (NASDAQ: VTRS) released its third‑quarter 2025 earnings, showing a 2 % year‑over‑year (YOY)...

Company Drug

Humanwell Healthcare Secures NMPA Approval to Launch First Fixed‑Dose Combination for Pulmonary Arterial Hypertension

Fineline Cube Nov 8, 2025

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its investigational compound HWH217 has received...

Company Drug

Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access

Fineline Cube Nov 8, 2025

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) announced a historic agreement with the...

Medical Device

Johnson & Johnson Launches ETHICON 4000 3D Laparoscopic Stapler in China

Fineline Cube Nov 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced today the commercial rollout of its ETHICON 4000 laparoscopic stapler...

Company

BeOne Medicines Posts $1.4 B Q3 2025 Revenue, Driven by BRUKINSA Momentum

Fineline Cube Nov 7, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released its third‑quarter 2025 financial results, reporting...

Company Drug

CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA​I Meeting

Fineline Cube Nov 7, 2025

China‑based CStone Pharmaceuticals (HKG: 2616) announced that the pre‑clinical results for its bispecific biologic CS2015...

Company Deals

AmacaThera Signs Exclusive Global License with Pacira BioSciences for AMT‑143, Up to $230 M Deal

Fineline Cube Nov 7, 2025

AmacaThera, the hydrogel‑technology biotech incubated by Viva BioInnovator (VBI), announced an exclusive worldwide licensing agreement...

Others

Sanofi’s Cablivi Wins China NMPA Approval – First Nanobody Drug for aTTP

Fineline Cube Nov 7, 2025

Sanofi (NASDAQ: SNY) announced that its anti‑vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing...

Others

Judge Rejects Pfizer’s Attempt to Block Novo Nordisk’s $10 bn Bid for Metsera

Fineline Cube Nov 7, 2025

Delaware Court of Chancery Judge Morgan Zurn denied Pfizer’s (NYSE: PFE) request for a temporary...

Company

Amgen Reports 12% YoY Sales Growth in Q3 2025, Raises Full‑Year Revenue Guidance

Fineline Cube Nov 7, 2025

US‑based biotech giant Amgen (NASDAQ: AMGN) posted its third‑quarter 2025 results, showing total sales of...

Company

AstraZeneca Posts 11% Y/Y Revenue Rise to $43.24 bn in First Nine‑Months of 2025

Fineline Cube Nov 7, 2025

AstraZeneca (AZ, NASDAQ: AZN) released its third‑quarter and nine‑month 2025 financial results, showing total revenues...

Policy / Regulatory

NHSA Concludes 2025 National Basic Medical Insurance Drug Catalogue Negotiation and Commercial Insurance Innovative Drug Price Talks

Fineline Cube Nov 6, 2025

The National Healthcare Security Administration (NHSA) wrapped up a week‑long series of negotiations and bidding...

Company Deals

XtalPi’s Ailux Strikes $345 Million Partnership with Eli Lilly to Co‑Develop Bispecific Antibodies

Fineline Cube Nov 6, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) disclosed that its wholly‑owned subsidiary Ailux...

Medical Device

Siemens Shanghai Gains NMPA Clearance for Prostate‑Cancer AI Detection Software

Fineline Cube Nov 6, 2025

Siemens Shanghai Medical Equipment Ltd. (SSME) announced that the National Medical Products Administration (NMPA) has...

Company Deals

HBM’s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co‑Develop In‑Vivo CAR‑T Platforms

Fineline Cube Nov 6, 2025

HBM Holdings Limited (HKG: 2142) announced that its wholly‑owned subsidiary Nona Biosciences (Suzhou) Co., Ltd....

Posts pagination

1 … 28 29 30 … 611

Recent updates

  • Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate
  • Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
  • Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
  • AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly
  • Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.